Daiichi Sankyo

Destiny 5 (B60)

NCT04622319

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Status:

Opening Soon

26459-200.png

III

Phase

Line of Therapy.png

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

HER2+

Investigational

Product

trastuzumab deruxtecan

Treatment Arms

o Trastuzumab deruxtecan

o Trastuzumab ematansine